CRISPR Therapeutics AG Stock News

One of the biggest opportunities in healthcare today centers around genome editing. According to analysts at Grand View Research, the global genome market is expected to expand at a compound annual growth rate of more than 16% until the end of the decade.

It's very tempting to pile into the stocks with the strongest positive momentum of the moment -- they've proven themselves and could continue along this path. But in many cases, you could set yourself up for a bigger win if you look to quality companies that have seen their stocks stumble in recent times.

Our genetics are like nature's roadmap. Our DNA dictates what color eyes we have, how tall we become, and our physical abilities.

The best investments are often stocks of companies offering goods and services that are perpetually in demand. Think entertainment, healthcare, or more recently, some consumer technologies.

CRSP's main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It's a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy's rollout has been slow due to its high cost, specialized centers, and lengthy required preconditioning. Still, CRSP will eventually receive 40% of Casgevy's profits through its partnership with VRTX.

Growth stocks have been rallying in recent weeks, and that's usually great news for Cathie Wood. The founder, CEO, and stock-picking ace of the Ark Invest family of exchange-traded funds (ETFs) has momentum on her side.

CRISPR Therapeutics' stock is down 20% since March, with ongoing high cash burn despite a robust $1.86 billion cash position. Casgevy's commercialization is slow, with over 65 treatment centers active but no recognized revenue yet, reflecting a complex administration process and gradual gene therapy adoption. Regulatory uncertainties under Dr. Vinay Prasad's FDA leadership could delay approvals...

CRISPR Therapeutics AG reported a Q1 net loss of $136m, but maintains a strong cash position with $1.86bn in cash and marketable securities. Casgevy, a gene therapy for Sickle Cell Disease, has seen slow uptake due to high costs and lengthy treatment processes, but potential remains high. Promising results from Crispr's in-vivo gene editing candidate CTX-310 show significant reductions in LDL a...